FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

類似資料

• FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
  著者:: Odogwu, Lauretta, 等
  出版事項: (2017)
• Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
  著者:: Čepulytė, Rūta, 等
  出版事項: (2020)
• Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
  著者:: Seo, Takuji, 等
  出版事項: (2020)
• Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
  著者:: Corcoran, Ryan B., 等
  出版事項: (2015)
• Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
  著者:: Dotsu, Yosuke, 等
  出版事項: (2020)